CHCWM – Cancer & Hematology Centers of West Michigan

M21-404 (Abbvie)

Description:  Advanced Solid Tumors:   ABBV-400 as Monotherapy-A Global First-in-Human Study   Mechanism of Action: Antibody drug conjugate targeting c-MET with a topoisomerase inhibitor payload   Target Patient Population: All solid tumors   Study Design: Study drug is administered IV every 3 weeks   For more information on this trial, read its profile on clinicaltrials.gov here.

C-1400-01 (AGEN1777) (Agenus, Inc.)

C-1400-01 (AGEN1777) (Agenus, Inc.) Description:  A Phase 1 Study Investigating AGEN1777 as a Single-Agent and in Combination with PD-1 Inhibition in Patients With Advanced Solid Tumors Mechanism of Action: bispecific antibody targeting TIGIT and CD96 (to enhance T and NK cell activation) Target Population:  All solid tumors.  To be given as single agent or in

ALKS 4230-003 (Alkermes Inc. )

ALKS 4230-003 (Alkermes Inc. ) Description:  Clinical and Immunologic Activity of Nemvaleukin Alfa With a less Frequent IV Dosing With Pembrolizumab and Impact on Tumor Microenvironment in Soloid Tumor Patients (Artistry-3) Mechanism of Action:  IL2 receptor agonist Target Patient Population: Cutaneous melanoma, Renal Cell, Triple Negative Breast, MMS Colorectal, Ovarian and any MSI-High solid tumors

19951-CL-0101 (Astellas)

Phase 1b Study of ASP1951, a GITR Agonistic Antibody, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

ALPN-202-NEON-1 (Alpine Immune Sciences)

ALPN-202 – NEON-1 (Alpine Immune Sciences) Description:  An open-Label Study of ALPN-202 In Subjects With Advanced Malignancies (NEON-1)  Mechanism of Action: Inhibits PDL1 and CTLA4, engages CD28 co-stimulator. Target Patient Population: Currently in expansion for Melanoma, Renal cell  and PDL1 positive cancers only Study Design: Study drug is administered IV every 1 or 3 weeks

ALPN-202-NEON-2 (Alpine Immune Sciences)

ALPN-202 – NEON-2 (Alpine Immune Sciences)  Description:  An open-Label Study of ALPN-202 Combined With PD-1 Inhibition In Subjects With Advanced Malignancies (NEON-2) Mechanism of Action: Inhibits PDL1 and CTLA4, engages CD28 co-stimulator in combination with Pembrolizumab. Target Patient Population:.  All solid tumors Study Design: Study drug is administered IV every 1 or 3 weeks  

BBI-20201001 (Bolt)

BBI-20201001 (Bolt) Description:   Phase 1 Study of BDC-1001 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced and HER2-Expressing Solid Tumors Mechanism of Action: Immune stimulating antibody drug conjugate – trastuzumab like antibody conjugated to a TLR7/8 payload.  Currently combination with Pembrolizumab. Target Patient Population: Advanced solid tumor patients with IHC

CA115-001 (Bristol Myers Squibb)

CA115-001 (Bristol Myers Squibb)  Description:   Phase 1b/2 Study of BMS-986442 in Combination with Nivolumab or Nivolumab and Chemotherapies in Participants with Advanced Solid Tumors and Non-small cell Lung Cancer Mechanism of Action:  Bispecific antibody TIGIT and CD96 Target Patient Population: Starting with dose escalation in advanced solid tumors with specific cohorts in combination with Nivolumab

CC-94676-  (Celgene)

CC-94676-  (Celgene) Description:  A Phase 1, Multi-Center, Open-Label, Dose Finding Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of CC-94676 In Subjects With Metastatic Castration-Resistant Prostate Cancer Mechanism of Action:  Oral Androgen Receptor Degrader Target Patient Population:  Prostate Cancer Study Design:  Drug is given orally daily.

CPI-0209-01 (Constellation)

CPI-0209-01 (Constellation) Description:   A Phase 1/2 Study of CPI-0209 Monotherapy and in Combination with Other Therapy in Patients with Advanced Solid Tumors Mechanism of Action:  EZH2  Inhibitor Target Patient Population:  In Phase 2 with slots for tumors with known ARID1A mutations in Lymphoma, Mesothelioma, Urothelial and Endometrial.  Study Design:  Drug is given orally daily.